ECSP045004A - Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes - Google Patents

Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes

Info

Publication number
ECSP045004A
ECSP045004A EC2004005004A ECSP045004A ECSP045004A EC SP045004 A ECSP045004 A EC SP045004A EC 2004005004 A EC2004005004 A EC 2004005004A EC SP045004 A ECSP045004 A EC SP045004A EC SP045004 A ECSP045004 A EC SP045004A
Authority
EC
Ecuador
Prior art keywords
inhibitors
treatment
17beta
depending
dehydrogenase type
Prior art date
Application number
EC2004005004A
Other languages
English (en)
Inventor
J Timothy
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP045004A publication Critical patent/ECSP045004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen compuestos de la fórmula (I): Prodrogas de los mismos, ó sales aceptables para uso farmacéutico de los compuestos ó de dichas prodrogas que son útiles como inhibidores de la 17b- hidroxiesteroide deshidrogenasa tipo 3. También se describen composiciones farmacéuticas que contienen dichos compuestos y su uso para el tratamiento ó la prevención de enfermedades andrógeno dependientes
EC2004005004A 2001-09-06 2004-03-04 Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes ECSP045004A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31771501P 2001-09-06 2001-09-06

Publications (1)

Publication Number Publication Date
ECSP045004A true ECSP045004A (es) 2004-04-28

Family

ID=23234950

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005004A ECSP045004A (es) 2001-09-06 2004-03-04 Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes

Country Status (29)

Country Link
US (3) US6903102B2 (es)
EP (1) EP1423381B1 (es)
JP (1) JP4320252B2 (es)
KR (1) KR100991616B1 (es)
CN (1) CN1551878B (es)
AR (1) AR036492A1 (es)
AT (1) ATE350375T1 (es)
AU (1) AU2002326823B2 (es)
BR (1) BR0212378A (es)
CA (1) CA2459311C (es)
CY (1) CY1106521T1 (es)
DE (1) DE60217363T2 (es)
DK (1) DK1423381T3 (es)
EC (1) ECSP045004A (es)
ES (1) ES2276950T3 (es)
HU (1) HUP0402629A3 (es)
IL (2) IL160065A0 (es)
MX (1) MXPA04002167A (es)
MY (1) MY141661A (es)
NO (1) NO327254B1 (es)
NZ (1) NZ530810A (es)
PE (1) PE20030703A1 (es)
PL (1) PL369108A1 (es)
PT (1) PT1423381E (es)
RU (1) RU2315763C2 (es)
SI (1) SI1423381T1 (es)
TW (1) TWI329108B (es)
WO (1) WO2003022835A1 (es)
ZA (1) ZA200401456B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
ES2347643T3 (es) * 2001-10-17 2010-11-03 Schering Corporation Piperin- y piperazinacetamidas como inhibidores de 17beta hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7132539B2 (en) * 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
ES2345146T3 (es) * 2002-11-18 2010-09-16 Schering Corporation Inhibidores de 17beta-hidroxiesteroides deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
AU2003293555A1 (en) 2002-12-17 2004-07-29 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7465739B2 (en) 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
TW200528110A (en) * 2003-12-17 2005-09-01 Schering Corp Pharmaceutical compositions
CN1930181A (zh) 2004-01-07 2007-03-14 恩多研究公司 螺旋12定向的甾族药品
US7138246B2 (en) 2004-03-01 2006-11-21 Bristol-Myers Squibb Company Methods for identifying or screening for agents that modulate 17β-HSD3
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7569725B2 (en) 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US8884061B2 (en) * 2006-03-03 2014-11-11 Colorado State University Research Foundation Compositions and methods of use of electron transport system inhibitors
ATE543798T1 (de) * 2006-04-24 2012-02-15 Lilly Co Eli Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
CA2649650C (en) * 2006-04-24 2014-01-14 Eli Lilly And Company Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
SG172685A1 (en) * 2006-06-28 2011-07-28 Amgen Inc Glycine transporter-1 inhibitors
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8080540B2 (en) * 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
US8273883B2 (en) * 2007-02-09 2012-09-25 Kaneka Corporation Method for producing optically active 2-arylpiperazine derivative
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
BR112014003567A2 (pt) 2011-08-16 2018-08-14 Mt Sinai School Of Medicine composto, uso de um composto, e, composição farmacêutica
EP2961409A1 (en) * 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
TW201512215A (zh) 2013-06-25 2015-04-01 Forendo Pharma Ltd 治療活性雌三烯噻唑衍生物
AU2014300894A1 (en) 2013-06-25 2016-01-28 Forendo Pharma Ltd Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
JP6456373B2 (ja) 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
MX2016002479A (es) * 2013-09-12 2016-05-31 Pfizer Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
CN103755626A (zh) * 2014-01-23 2014-04-30 安徽安腾药业有限责任公司 一种贝托斯汀关键中间体的合成方法
FR3017868A1 (fr) * 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10413557B2 (en) 2014-12-23 2019-09-17 Forendo Pharma Ltd. Prodrugs of 17.BETA.-HSD1-inhibitors
WO2016102775A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
CN110621669A (zh) 2017-05-04 2019-12-27 巴斯夫欧洲公司 防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
SG11201911776PA (en) 2017-06-08 2020-01-30 Forendo Pharma Ltd 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
CA3122049C (en) 2018-12-05 2023-10-17 Forendo Pharma Ltd Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
MA56457A (fr) 2019-07-02 2022-05-11 Regeneron Pharma Modulateurs de hsd17b13 et leurs procédés d'utilisation
MX2022002282A (es) 2019-08-28 2022-03-25 Unilever Ip Holdings B V Compuestos novedosos para aclarar la piel.
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3590389T1 (de) 1984-08-02 1986-08-28 Schering Corp., Kenilworth, N.J. Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer
PH30747A (en) 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
DK0595796T3 (da) 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
CA2062973C (en) 1989-07-07 2003-09-23 Fernand Labrie Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
IL99320A (en) 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
ATE122673T1 (de) * 1990-10-10 1995-06-15 Schering Corp Pyridin- und pyridin-n-oxid-derivate von diarylmethyl- piperidinen oder piperazinen, deren zusammensetzungen und anwendung.
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
DE69303605T2 (de) 1992-03-27 1997-01-23 Schering Corp Unverbrückte bis-aryl-carbinol-derivate, zusammensetzungen und ihre verwendung
EP0666856B1 (en) 1992-10-28 2000-01-05 MERCK SHARP & DOHME LTD. 4-arylmethyloxymethyl piperidines as tachykinin antagonists
JPH08504435A (ja) 1992-12-14 1996-05-14 メルク シヤープ エンド ドーム リミテツド タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
CZ285893B6 (cs) 1993-05-17 1999-11-17 Endorecherche Inc. Antiandrogenní sloučenina, její prekursor a farmaceutický prostředek ji obsahující
EP0702681A1 (en) 1993-06-07 1996-03-27 Merck & Co. Inc. Spiro-substituted azacycles as neurokinin antagonists
JPH09507500A (ja) 1994-01-13 1997-07-29 メルク シヤープ エンド ドーム リミテツド ｇｅｍ二置換アザシクロ系のタキキニン拮抗薬
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5688960A (en) 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
US5789422A (en) 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5945428A (en) 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US5783579A (en) 1996-12-20 1998-07-21 Schering Corporation Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists
WO2000017163A1 (en) * 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
US6063926A (en) 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
US6204265B1 (en) 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
DE60018707T2 (de) 1999-01-25 2006-02-09 Smithkline Beecham Corp. Anti-androgene und verfahren zur behandlung von krankheiten
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
HUP0301391A3 (en) * 2000-02-11 2010-03-29 Vertex Pharma Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use

Also Published As

Publication number Publication date
MY141661A (en) 2010-05-31
IL160065A0 (en) 2004-06-20
US6903102B2 (en) 2005-06-07
CA2459311C (en) 2010-08-03
US20040132736A1 (en) 2004-07-08
RU2315763C2 (ru) 2008-01-27
US20060069103A1 (en) 2006-03-30
PL369108A1 (en) 2005-04-18
SI1423381T1 (sl) 2007-04-30
CY1106521T1 (el) 2012-01-25
WO2003022835A1 (en) 2003-03-20
IL160065A (en) 2009-07-20
PE20030703A1 (es) 2003-08-21
DE60217363T2 (de) 2007-10-11
HK1062677A1 (en) 2004-11-19
DK1423381T3 (da) 2007-05-07
KR100991616B1 (ko) 2010-11-04
KR20040031042A (ko) 2004-04-09
EP1423381A1 (en) 2004-06-02
HUP0402629A2 (hu) 2005-05-30
AR036492A1 (es) 2004-09-15
US20060014755A1 (en) 2006-01-19
CN1551878A (zh) 2004-12-01
EP1423381B1 (en) 2007-01-03
RU2004110410A (ru) 2005-10-20
CA2459311A1 (en) 2003-03-20
US7432268B2 (en) 2008-10-07
JP4320252B2 (ja) 2009-08-26
NO20041452L (no) 2004-06-04
MXPA04002167A (es) 2004-06-29
US7138396B2 (en) 2006-11-21
NO327254B1 (no) 2009-05-25
ZA200401456B (en) 2004-10-19
NZ530810A (en) 2006-05-26
DE60217363D1 (de) 2007-02-15
HUP0402629A3 (en) 2009-09-28
ES2276950T3 (es) 2007-07-01
CN1551878B (zh) 2011-08-10
JP2005502705A (ja) 2005-01-27
BR0212378A (pt) 2004-10-19
AU2002326823B2 (en) 2005-12-15
PT1423381E (pt) 2007-04-30
ATE350375T1 (de) 2007-01-15
TWI329108B (en) 2010-08-21

Similar Documents

Publication Publication Date Title
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
ECSP034914A (es) "azaindoles"
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
UY27516A1 (es) Bencimidazoles
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
ATE433447T1 (de) Pyrimiidinverbindungen
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
CL2003002770A1 (es) Compuestos derivados de pirrol e imiddazol; composiciones farmaceuticas que los contienen; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de enfermedades que estan asociadas con la modulacion de los receptores a canabinoides
UY28342A1 (es) Nuevos compuestos
GT200100132A (es) Derivados de pirazol
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
CL2004000848A1 (es) Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
DE60324544D1 (de) Muskarin antagonisten
ATE300541T1 (de) Pyrazolopyridinderivate
CO5611124A2 (es) Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso